Monoclonal antibody 55 (CD10) and complement used for purging autologous bone marrow in common acute lymphoblastic leukemia.
A CD10 monoclonal antibody 55 (McAb55) was intended for purging residual common acute lymphoblastic leukemia antigen (CALLA) positive leukemic cells from autotransplants of common acute lymphoblastic leukemia (C-ALL) patients. It was found that after two rounds of McAb55 and complement treatment, 4-5 logs of CALLA+ cells were removed from bone marrow detected by clonogenic assay. The standardization of separation, purgation and preservation of bone marrow for C-ALL patients' autotransplants was then set as follows: Following the carboxymethyl starch sedimentation and Ficoll-Hypaque gradient separation, the isolated mononuclear cells (MNCs) were treated with McAb55 and complement twice and kept in room temperature for 48-72 hours prior to infusion. This procedure resulted in the removal of more than 99% of CALLA+ cells, recovery of 10-30% MNCs, and leaving the hematopoiesis stem cells intact. After the intensive cytoreductive therapy, 4 patients with C-ALL received the purged autotransplants giving timely recovery of the hematopoietic function. The patients were all remaining in remission status for more than 40-250 days so far.
Bai
Y
Y
Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing.
Piao
X H
XH
Luo
Q L
QL
Mao
B Z
BZ
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D003165:Complement System Proteins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000601:surgery*
D000911:Antibodies, Monoclonal; D003165:Complement System Proteins